Shilpi Agrawal Data-verified

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

Postdoctoral Research Scientist III

University of Arkansas

Last publication 2025 Last refreshed 2026-05-23

postdoc

sagrawal@uark.edu

11 h-index 59 pubs 541 cited

Research Areas

Links

ORCID

OverviewAI-generated summary

Shilpi Agrawal's research focuses on understanding the molecular mechanisms underlying protein behavior and interactions, particularly concerning fibroblast growth factors (FGFs) and their binding partners. Her work has investigated the structural forces that govern protein stability and unfolding, employing techniques such as molecular dynamics simulations to estimate binding affinities. Agrawal has also explored the stabilization of monomeric human fibroblast growth factor 1 by heparin binding. More recently, her research has extended into the application of CRISPR-Cas9 technology, with publications addressing delivery challenges for Duchenne muscular dystrophy and the advancement of CRISPR-based solutions for COVID-19 diagnosis and therapeutics. She has also focused on optimizing recombinant Cas9 expression for enhanced protein purification and genome editing applications. Agrawal has a notable record of collaboration with researchers at the University of Arkansas at Fayetteville, including Christopher E. Nelson, Thallapuranam Krishnaswamy Suresh Kumar, Made Harumi Padmaswari, and Mahmoud Moradi, with whom she shares multiple publications. Her scholarship metrics include an h-index of 11, 55 total publications, and 479 total citations.

Metrics

h-index: 11
Publications: 59
Citations: 541

Selected Publications

Beyond the Cut: Long-read sequencing reveals complex genomic and transcriptomic changes in AAV-CRISPR therapy for Duchenne Muscular Dystrophy (2025)

DOI OpenAlex
Standardizing a Protocol for Streamlined Synthesis and Characterization of Lipid Nanoparticles to Enable Preclinical Research and Education (2025)

1 citation DOI OpenAlex
A dual-fluorescence assay for gene delivery vehicle screening in macrophages with an inflammation-inducible reporter construct (2025)

DOI OpenAlex
Unraveling Attention-Deficit/Hyperactivity Disorder Etiology: Current Challenges and Future Directions in Treatment (2025)

1 citation DOI OpenAlex
Preclinical development of genome editing to treat Duchenne muscular dystrophy by exon skipping (2025)

2 citations DOI OpenAlex
Structural Stability Comparisons Between Natural and Engineered Group II Chaperonins: Are Crenarchaeal “Heat Shock” Proteins Also “pH Shock” Resistant? (2024)

DOI OpenAlex
Advancing CRISPR-Based Solutions for COVID-19 Diagnosis and Therapeutics (2024)

9 citations DOI OpenAlex
Resistance to Acetyl Coenzyme A Carboxylase (ACCase) Inhibitor in Lolium multiflorum: Effect of Multiple Target-Site Mutations (2024)

1 citation DOI OpenAlex
Precision and efficacy of RNA-guided DNA integration in high-expressing muscle loci (2024)

2 citations DOI OpenAlex
Optimizing Recombinant Cas9 Expression: Insights from E. coli BL21(DE3) Strains for Enhanced Protein Purification and Genome Editing (2024)

5 citations DOI OpenAlex
Precision and efficacy of RNA-guided DNA integration in high-expressing muscle loci (2024)

2 citations DOI OpenAlex
CRISPR-Cas9 Unleashed: Gene-Slicing Adventures in the Cancer Battlefield (2024)

1 citation DOI OpenAlex
Delivery challenges for CRISPR—Cas9 genome editing for Duchenne muscular dystrophy (2023)

10 citations DOI OpenAlex
Overexpression and cell-penetrating peptide-mediated delivery of Cas9 and its variant(s) for targeted genome editing (2023)

2 citations DOI OpenAlex
Binding affinity estimation from restrained umbrella sampling simulations (2022)

54 citations DOI OpenAlex